Jazz Pharmaceuticals PLC $JAZZ Position Boosted by Ellis Investment Partners LLC

Ellis Investment Partners LLC grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,045 shares of the specialty pharmaceutical company’s stock after purchasing an additional 707 shares during the period. Ellis Investment Partners LLC’s holdings in Jazz Pharmaceuticals were worth $641,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth about $62,362,000. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 41.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock valued at $165,245,000 after acquiring an additional 391,660 shares during the period. Perpetual Ltd lifted its position in shares of Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company’s stock valued at $118,212,000 after acquiring an additional 357,784 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after purchasing an additional 293,360 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after purchasing an additional 209,667 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.0%

Shares of Jazz Pharmaceuticals stock opened at $135.43 on Monday. The firm has a market cap of $8.22 billion, a price-to-earnings ratio of -20.12, a P/E/G ratio of 8.32 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The stock has a 50-day simple moving average of $125.87 and a 200-day simple moving average of $115.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on JAZZ shares. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Royal Bank Of Canada lifted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Truist Financial increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Finally, The Goldman Sachs Group raised their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a report on Friday, August 29th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $178.93.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.